Fig. 1 · Structure

Documents & Downloads

Doxercalciferol

Cat. No. A10335 CAS 54573-75-0
Doxercalciferol is a synthetic analog of ergocalciferol (vitamin D2). It suppresses parathyroid synthesis and secretion.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Doxercalciferol shows VDR-associated pharmacology in vivo. In diabetic mice, low-dose treatment produced a stronger albuminuria response with podocyte-targeted VDR overexpression than in wild-type animals. This model supports a role for VDR context but does not measure direct receptor affinity or establish an agonist IC50. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Doxercalciferol Research Summary

This section summarizes 1 in vitro study and 2 in vivo studies of Doxercalciferol from 3 published references. In vitro models include human SH-SY5Y neuroblastoma cells stably overexpressing APP695.

Doxercalciferol In Vitro Studies

In APP695-expressing SH-SY5Y cells, 100 nM doxercalciferol for 24 hours reduced the conditioned-medium total Aβ signal to 70.9 ± 8.6% of ethanol control (mean ± SEM; n = 3; p = 0.037). This assay observation does not establish a specific antiamyloid mechanism or treatment efficacy in animals or humans. [2]

Conditioned-medium Aβ endpoint in APP695-expressing SH-SY5Y cells

Cell-based study · Human SH-SY5Y neuroblastoma cells stably overexpressing APP695. [2]

After 100 nM doxercalciferol for 24 hours, total secreted Aβ was 70.9 ± 8.6% of solvent control (mean ± SEM; n = 3; p = 0.037). This is a conditioned-medium assay endpoint; it does not by itself distinguish production, degradation or cell-number effects. It does not establish efficacy in Alzheimer disease.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Total secreted Aβ in conditioned mediumRelative Aβ level 70.9 ± 8.6% of solvent control; mean ± SEM; n = 3; p = 0.037[2]

Literature-Reported Treatment Conditions

Treatment concentration
100 nM
Exposure duration
24 hours (8 + 16 hours, as described in Methods 4.3.1)
Method
Cell incubation; serum reduced 16 hours before treatment, with incubation in up to 2.5% FCS/DMEM.
Vehicle
Ethanol; final solvent-control concentration 1‰
Reported limits
No IC50 was measured for this endpoint. The exact serum percentage for Figure 2(a) is not assigned in the general method. Supplementary Figure S1 was not retrieved, so compound-specific viability control coverage could not be confirmed.
Methods and source locations

Compound reported in the paper: Doxercalciferol; Compound label in the paper: 1-hydroxylated vitamin D2 analogue

A parent-compound cell-assay observation; no inference of brain exposure, in vivo treatment efficacy, direct VDR affinity or Adooq material equivalence.

Results 2.1; Figure 2(a) and caption; Methods 4.1–4.5 and 4.12

Total secreted Aβ in conditioned medium: Immunoprecipitation followed by Western blot and densitometry; control set to 100%; unpaired Student’s t test — Results 2.1; Figure 2(a) caption; Methods 4.5 and 4.12

Doxercalciferol In Vivo Studies

In hyperphosphatemic 5/6-nephrectomized rats, doxercalciferol lowered serum PTH while increasing serum calcium and the calcium–phosphate product. These mineral changes limit interpretation of PTH suppression as a uniformly favorable response. The PTH-mRNA figure does not mark a significant doxercalciferol-versus-vehicle reduction. [3]

PTH suppression and mineral changes in hyperphosphatemic uremic rats

Animal study · Male Sprague-Dawley rats after 5/6 nephrectomy, fed a hyperphosphatemia-inducing diet; n = 8–11 per group. [3]

In this two-week treatment cohort, doxercalciferol reduced serum PTH relative to NX vehicle while increasing total and ionized calcium and the calcium–phosphate product. The PTH-mRNA bar was lower than NX vehicle, but Figure 4 does not mark this doxercalciferol comparison as significant versus NX vehicle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Serum intact PTHGroup mean 445 ± 135 versus 2504 ± 579 pg/mL (NX vehicle); P < .01 versus NX vehicle; mean ± SEM; n = 8–11 per group[3]
Total serum calciumGroup mean 10.93 ± 0.23 versus 8.99 ± 0.35 mg/dL (NX vehicle); P < .001 versus NX vehicle; mean ± SEM; n = 8–11 per group[3]
Serum calcium × phosphate productGroup mean 122.9 ± 10.6 versus 89.1 ± 4.0 (mg/dL)² (NX vehicle); P < .001 versus NX vehicle; mean ± SEM; n = 8–11 per group[3]
Total serum phosphateGroup mean 11.31 ± 1.05 versus 10.09 ± 0.76 mg/dL (NX vehicle); no significant drug effect versus NX vehicle reported; mean ± SEM; n = 8–11 per group[3]
Parathyroid PTH mRNAQualitative figure result Lower plotted mean than NX vehicle; no significance marker for doxercalciferol versus NX vehicle in Figure 4(b). No exact value extracted from the graph.[3]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Three times per week
Treatment course
Two weeks after four weeks on the hyperphosphatemia-inducing diet
Vehicle
5% ethanol + 95% propylene glycol, 0.4 mL/kg
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Doxercalciferol, hyperphosphatemic NX rats
0.33 μg/kg
NX vehicle; sham vehicle provides a disease baseline; paricalcitol comparator was also included.Lower serum PTH with increased serum calcium and calcium–phosphate product; serum phosphate was not significantly changed versus NX vehicle.[3]
Doxercalciferol, hyperphosphatemic NX rats
Model: Male Sprague-Dawley 5/6 NX rats on 0.9% phosphorus/0.6% calcium diet
Reported limits: No Adooq lot testing is established.
Methods and source locations

Compound reported in the paper: Doxercalciferol; Compound label in the paper: 1α-hydroxyvitamin D2

Animal pharmacology of parent doxercalciferol; the separate active-metabolite pig-cell results are not parent-compound evidence.

Methods 2.1–2.4; Results hyperphosphatemic-diet cohort; Table 1; Figure 4 and caption

Serum intact PTH: Rat intact PTH ELISA — Table 1 (values and significance); Figure 4(a) (pg/mL unit); Methods 2.3

Total serum calcium: Abbott Aeroset — Table 1; Methods 2.3

Serum calcium × phosphate product: Product of measured total serum calcium and phosphate — Table 1

Total serum phosphate: Abbott Aeroset — Table 1; Results hyperphosphatemic-diet cohort; Methods 2.3

Parathyroid PTH mRNA: Real-time RT-PCR, normalized to GAPDH and expressed relative to sham vehicle (100%) — Figure 4(b) and caption; Methods 2.4

Doxercalciferol, hyperphosphatemic NX rats · Methods 2.1–2.4; Results hyperphosphatemic-diet cohort; Table 1; Figure 4 and caption

Low-dose doxercalciferol response depends on podocyte VDR expression in diabetic mice

Animal study · STZ-diabetic male DBA/2J wild-type and podocyte human-VDR transgenic mice; n = 7–9 per group. [1]

At 30 ng/kg for 16 weeks, doxercalciferol had little effect on albuminuria in wild-type mice, whereas the transgenic treatment group showed much lower albuminuria. Vehicle-treated transgenic mice also had less albuminuria than wild-type vehicle controls. This supports a VDR-associated, genotype-dependent response, not a receptor-binding potency estimate.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Urinary albumin-to-creatinine ratio over timeLongitudinal ACR Little treatment effect in WT mice; albuminuria nearly blocked in Tg mice according to Results. Figure 2(a): n = 7–9 per group; Tg+Dox marked P < 0.001 versus WT+vehicle at weeks 8, 12 and 16. No exact curve values extracted.[1]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Three times per week
Treatment course
16 weeks
Vehicle
60:40 propylene glycol/H2O
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Wild-type + doxercalciferol
30 ng/kg
Genotype-matched WT vehicle group; nondiabetic untreated controlsLittle effect on progression of albuminuria at this low dose.[1]
Podocyte hVDR transgenic + doxercalciferol
30 ng/kg
Tg vehicle and WT vehicle groups; Tg vehicle already had reduced albuminuriaAlbuminuria nearly blocked; late timepoints marked P < 0.001 versus WT vehicle. The plotted significance comparison is not a formal genotype × treatment interaction test.[1]
Wild-type + doxercalciferol
Model: Diabetic male DBA/2J WT mice
Reported limits: No Adooq lot testing is established.
Podocyte hVDR transgenic + doxercalciferol
Model: Diabetic male DBA/2J mice with podocyte-targeted human VDR transgene
Reported limits: No Adooq lot testing is established.
Methods and source locations

Compound reported in the paper: Doxercalciferol; Compound label in the paper: Dox

Low-dose parent-compound animal response in a genetically modified diabetic mouse model; no Adooq lot validation or universal renoprotection claim.

Results paragraph beginning “We subjected WT and Tg mice”; Figure 2(a) and caption; Table 1; Concise Methods: Diabetic Animal Models and Treatment

Urinary albumin-to-creatinine ratio over time: Urinary albumin and creatinine measured with commercial kits; spot urine collected monthly — Figure 2(a) and caption; Results second experiment paragraph; Concise Methods: Diabetic Animal Models and Treatment

Wild-type + doxercalciferol · Results paragraph beginning “We subjected WT and Tg mice”; Figure 2(a) and caption; Table 1; Concise Methods: Diabetic Animal Models and Treatment

Podocyte hVDR transgenic + doxercalciferol · Results paragraph beginning “We subjected WT and Tg mice”; Figure 2(a) and caption; Table 1; Concise Methods: Diabetic Animal Models and Treatment

Specifications

Manufacturer Adooq Bioscience
CAS Number 54573-75-0
Formula C28H44O2
Molecular Weight 412.65
SMILES
C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 71 mg/mL (172.05 mM)
Water Insoluble
Ethanol 60 mg/mL (145.4 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Doxercalciferol Research References

  1. [1] Wang Y, Deb DK, Zhang Z, et al. Vitamin D receptor signaling in podocytes protects against diabetic nephropathy. Journal of the American Society of Nephrology : JASN (2012). PMID: 23123403 DOI: 10.1681/asn.2012040383 Source material
  2. [2] Grimm MOW, Thiel A, Lauer AA, et al. Vitamin D and Its Analogues Decrease Amyloid-β (Aβ) Formation and Increase Aβ-Degradation. International journal of molecular sciences (2017). PMID: 29257109 DOI: 10.3390/ijms18122764 Source material
  3. [3] Wu-Wong JR, Nakane M, Gagne GD, et al. Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis. International journal of endocrinology (2010). PMID: 20204178 DOI: 10.1155/2010/621687 Source material

Added to your cart

View Cart Checkout
Loading...